This study is testing a drug called CX-5461 in people with advanced solid tumors, specifically those affecting the pancreas, prostate, breast, or ovary. To join, you must have a specific genetic change (mutation) in BRCA1/2, PALB2, or other genes related to Homologous Recombination Deficiency (HRD). The main goal is to find a safe and tolerable dose of CX-5461 for future studies. Researchers will also look at how well CX-5461 works against the cancer and its effects on your quality of life. CX-5461 works by targeting cancer cells that have these specific genetic changes. The study plans to enroll 52 participants, but its current status is unclear.

Study design

This is an open-label, multi-center study, meaning both you and your doctors will know you are receiving CX-5461. It aims to enroll 52 participants.

What's involved

CX-5461 is given by IV infusion on Day 1 and Day 8 of a 28-day cycle. Safety will be reviewed every 4 weeks until all patients are enrolled and evaluated for toxicity.

Compensation

Not stated in the trial record.

Follow-up

Safety data will be reviewed every 4 weeks from the date of the first patient's enrollment until all patients have been enrolled and evaluated for toxicity.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.